Follow-on roundup: Dermira, resTORbio, NanoString

Dermira raised $130 million in an upsized offering that followed closely after its eczema readout this week, while resTORbio and NanoString also priced follow-ons late Tuesday.

Dermira Inc. (NASDAQ:DERM) sold 9.8 million shares at $13.25, a 5% premium to its closing price of $12.61 on Monday, when it proposed after market hours to raise $110 million. The company's shares gained 84% on Monday after Dermira said anti-IL-13 mAb lebrikizumab met the primary endpoint in a Phase IIb trial to treat atopic dermatitis; the stock rose another 12% on Tuesday. A Phase III program is to start this year (see "Dermira Jumps on Phase IIb Atopic Dermatitis Readout")...